Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment
Authors:
- Natascha RoehlenNRNatascha Roehlen
- Marion MullerMMMarion Muller
- Zeina NehmeZNZeina Nehme
- Emilie CrouchetECEmilie Crouchet
- Frank JühlingFJFrank Jühling
- Fabio Del ZompoFZFabio Del Zompo
- Sara CherradiSCSara Cherradi
- Francois H.T. DuongFDFrancois H.T. Duong
- Nuno AlmeidaNANuno Almeida
- Antonio SavianoASAntonio Saviano
- Mirian Fernández-VaqueroMFMirian Fernández-Vaquero
- Tobias RiedlTRTobias Riedl
Open Access
- 26 October 2022
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (2) , 343-355
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Immunotherapies for hepatocellular carcinomaNature Reviews Clinical Oncology, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic featuresJournal of Hepatology, 2021
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- Emerging role of tumor cell plasticity in modifying therapeutic responseSignal Transduction and Targeted Therapy, 2020
- Molecular and histological correlations in liver cancerJournal of Hepatology, 2019
- Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodyNature Biotechnology, 2015
- Regulation of innate and adaptive immunity by NotchNature Reviews Immunology, 2013
- HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor ComplexCell Host & Microbe, 2013
- Transcriptome classification of HCC is related to gene alterations and to new therapeutic targetsHepatology, 2006